CTIS2022-501547-33-01进行中（未招募）1 期
Single-blind, investigator-initiated, randomized, controlled trial to assess the safety and efficacy of intravenous corticosteroid therapy to treat patients with acute myocarditis with mildly reduced left ventricular ejection fraction - MYTHSMR2023-07
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 205
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Age 18 years or older and below 70 years (18-69 years), LVEF<50% and LV-EDD<56 mm (parasternal long-axis view) on echocardiogram, Increased troponin (3x URL) at the time of randomization, Clinically suspected myocarditis with onset of cardiac symptoms within 3 weeks from randomization;, Excluded coronary artery disease by coronary angiogram in subjects =46 years of age, in case myocarditis is not histologically proven, Randomization within 120 hours from hospital admission, Endomyocardial biopsy (EMB) is not considered necessary before randomization and performing EMB is based on the decision of the local team, Patient has voluntarily signed and dated an informed consent form (ICF), approved by an Ethics Committee (EC) or institutional review board (IRB), after the nature of the study has been explained and the patient has had the opportunity to ask questions.
排除标准
- •Known systemic autoimmune disorder or other conditions at the time of randomization where immunosuppression is assumed useful. Patients in whom a systemic autoimmune disorder will be diagnosed during hospitalization will be included in the study if randomized, including patients with a diagnosis of cardiac sarcoidosis or GCM). Both patients included in the corticosteroids-treatment arm or in the placebo-treatment arm can receive the standard immunosuppressive therapy used in the center since the diagnosis, Myocarditis associated with the ongoing administration of anti-cancer immune checkpoint inhibitor (ICI) agents, Previously known chronic cardiac disease, Evidence of active bacterial or fungal infectious disease (presence of fever or increased C-reactive protein are not considered exclusion criteria), or suspected bacterial/fungal infection associated with increased levels of procalcitonin (cut-off >10 ng/mL), if the laboratory exam is available in the center, Known chronic infective disease, such as HIV infection or tuberculosis, Out of hospital cardiac arrest before randomisation, Contraindication for CMRI, Echocardiographic presence of images suggestive of other cardiac diseases (i.e. endocarditis), Participants involved in another clinical trial, Pregnant women (known pregnancy) or POSITIVE human chorionic gonadotropin (HCG) test measures (urine/blood) for women of 18-50 years of age, Any other significant disease with expected life expectancy <12 months (i.e., evidence of irreversible severe brain injury) or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial, If LVEF<41%, an N-terminal pro–B-type natriuretic peptide (NT-proBNP) concentration of 1600 pg/mL or more or a B-type natriuretic peptide (BNP) concentration of 400 pg/mL or more; (if LVEF 41%-<50% any NT-proBNP or BNP concentration is allowed)., Patients already on oral/IV chronic corticosteroid therapy or other chronic immunosuppressive therapies, Contraindication to corticosteroids, including history of previous (steroid) psychosis, allergies to this medication and its excipients;, Patients with persistent peripheral eosinophilia (persistent eosinophil count >7% of the leukocytes) or known hypereosinophilic syndrome at the time of randomization
研究者
相似试验
已完成
不适用
Single-investigator, randomized, double-blind, placebo-controlled trial of the efficacy and safety of oral antibiotics versus placebo in recurrent seropositive and seronegative Lyme diseaseRecurrent Lyme diseaseInfections and InfestationsISRCTN19325889yme Disease Practice and Research (USA)216
尚未招募
不适用
Prospective, randomized, subject single-blind, double-arm study to evaluate the outcome of ADM without basement membrane in prosthetic breast reconstructioKCT0005852Asan Medical Center60
尚未招募
4 期
Safety and immunogenicity of a booster dose of inactivated Vero-cell derived Japanese Encephalitis vaccine (JEVAC) in children whom primed with live attenuated JE vaccine.Immungenicity of booster dose of inactivated or live attenuated JE vaccine in children 20-30 month whom had primed with any live attenuated JE vaccine to ensure prevention of Japanese Encephalitis.Japanese encephalitis, JE vaccine, inactivated JE vaccine, live attenuated JE vaccine, , immunogenicity, safetyTCTR20220412006Biovalys Co., LTD140
已完成
不适用
Randomized, ControlleD, Single Blinded, ProspEctive, MuLtIcenter Study EValuating Anatomic versus Targeted lead placement for Burst DR Therapy during the Trial Evaluation periodNL-OMON45537St. Jude Medical40
进行中（未招募）
1 期
Study of safety and efficacy of CFZ533 in type 1 diabetes pediatric and young adult subjects.EUCTR2018-004553-25-ITOVARTIS PHARMA AG102